Related Experiment Video
Updated: May 21, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Treatment of Behçet's disease yesterday and today]
C M E Deuter1, M Zierhut, D Doycheva
1Department für Augenheilkunde, Universitäts-Augenklinik, Universitätsklinikum Tübingen, Schleichstr. 12-16, 72076, Tübingen, Deutschland. christoph.deuter@med.uni-tuebingen.de
Abstract:
Uveitis due to Behçet's disease belongs to those types of intraocular inflammation with a poor visual prognosis. Despite early treatment with corticosteroids and immunosuppressants, patients often become blind. With the so-called biologicals, highly effective drugs are now available which very rapidly lead to quiescence of intraocular inflammation and which successfully avoid further uveitis relapse. Recently, an interdisciplinary group of experts on behalf of the EULAR developed nine recommendations for the treatment of Behçet's disease. Two of these address ocular involvement. Compared with TNF alpha antagonists, interferon alpha offers the advantage that even after cessation of treatment a high percentage of patients remain in remission. This article provides an overview on current medical treatment of ocular Behçet's disease.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acute Pyelonephritis II: Diagnostic Studies and Management
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care